22.12.2019Bioncotech Therapeutics Announces Oncology Clinical Trial Collaboration with MSD Phase II Trial

Press Release
14.11.2019Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

Press Release
11.11.2019F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

 

Press Release
09.09.2019Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System

 

Press Release
26.04.2019Acutus Medical’s New Contact Mapping Software Receives CE Mark

 

Press Release
18.04.2019Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA

Press Release
08.04.2019F2G appoints Dr Patrick Vink as Chairman

Press Release
02.04.2019Aura Biosciences Completes $40 Million Series D Financing

 

Press Release
22.02.2019Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans

 

Press Release
05.10.2018Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock

Press Release